Literature DB >> 21908856

New role of microRNA: carcinogenesis and clinical application in cancer.

Luqing Zhao1, Xue Chen, Ya Cao.   

Abstract

MicroRNA (miRNA) is a cluster of small non-encoding RNA molecules of 21-23 nucleotides in length, which controls the expression of target gene at the post-transcriptional level. Recent researches have indicated that miRNA plays an essential role in carcinogenesis, such as affecting the cell growth, differentiation, apoptosis, and cell cycle. Nowadays, multiple promising roles of miRNA involved in carcinogenesis are emerging, and it is shown that miRNA closely relates to the process of epithelial-mesenchymal transition (EMT), the regulation of cancer stem cells (CSCs), the development of tumor invasion and migration. miRNA also acts as a biomarker stably expressed in serum and provides new target for molecular target therapy of various cancers. The aim of this review is to illustrate the new role of miRNA in carcinogenesis and highlight the new prospects of miRNA in cancer clinical application, such as in serological diagnosis and molecular-targeted therapeutics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21908856     DOI: 10.1093/abbs/gmr080

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  22 in total

1.  miR-33a levels in hepatic and serum after chronic HBV-induced fibrosis.

Authors:  Chuan-Feng Huang; Cheng-Chao Sun; Fang Zhao; Ya-Dong Zhang; De-Jia Li
Journal:  J Gastroenterol       Date:  2014-08-26       Impact factor: 7.527

2.  Serum microRNA expression profile as a biomarker for the diagnosis of pertussis.

Authors:  Yiyue Ge; Kangchen Zhao; Yuhua Qi; Xiaoyan Min; Zhiyang Shi; Xian Qi; Yunfeng Shan; Lan Cui; Minghao Zhou; Yong Wang; Hua Wang; Lunbiao Cui
Journal:  Mol Biol Rep       Date:  2012-10-18       Impact factor: 2.316

3.  MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines.

Authors:  Pasqualino de Antonellis; Lucia Liguori; Annarita Falanga; Marianeve Carotenuto; Veronica Ferrucci; Immacolata Andolfo; Federica Marinaro; Immacolata Scognamiglio; Antonella Virgilio; Giuseppe De Rosa; Aldo Galeone; Stefania Galdiero; Massimo Zollo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-01-26       Impact factor: 3.000

4.  Research on miRNA-195 and target gene CDK6 in oral verrucous carcinoma.

Authors:  Z Deng; Y Wang; X Fang; F Yan; H Pan; L Gu; C Xie; Y Li; Y Hu; Y Cao; Z Tang
Journal:  Cancer Gene Ther       Date:  2017-06-16       Impact factor: 5.987

Review 5.  MicroRNA-21 is a novel promising target in cancer radiation therapy.

Authors:  Jia Liu; Hongcheng Zhu; Xi Yang; Yangyang Ge; Chi Zhang; Qin Qin; Jing Lu; Liangliang Zhan; Hongyan Cheng; Xinchen Sun
Journal:  Tumour Biol       Date:  2014-01-21

6.  miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma.

Authors:  Ruijing Lu; Ziliang Ji; Xiaoqing Li; Qingna Zhai; Chunjuan Zhao; Zhimao Jiang; Shiqiang Zhang; Liping Nie; Zhendong Yu
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-03       Impact factor: 4.553

Review 7.  MicroRNA-21 gene and cancer.

Authors:  Yong Huang; You Bing Yang; Xiao Hui Zhang; Xue Li Yu; Zhan Bin Wang; Xiang Chao Cheng
Journal:  Med Oncol       Date:  2013-01-01       Impact factor: 3.064

Review 8.  The role of cancer stem cells and miRNAs in defining the complexities of brain metastasis.

Authors:  Ashhar S Ali; Aamir Ahmad; Shadan Ali; Bin Bao; Philip A Philip; Fazlul H Sarkar
Journal:  J Cell Physiol       Date:  2013-01       Impact factor: 6.384

9.  Serum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients.

Authors:  Prasant Yadav; Masroor Mirza; Kajal Nandi; S K Jain; R C M Kaza; Nita Khurana; P C Ray; Alpana Saxena
Journal:  Tumour Biol       Date:  2016-09-30

10.  MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients.

Authors:  Kai Doberstein; Nico Steinmeyer; Ann-Kathrin Hartmetz; Wolfgang Eberhardt; Michel Mittelbronn; Patrick N Harter; Eva Juengel; Roman Blaheta; Josef Pfeilschifter; Paul Gutwein
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.